CORTINOVIS DIEGO LUIGI

Crespi, V., Delcuratolo, M., Minuti, G., Montrone, M., Pilotto, S., Roca, E., et al. (2025). Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer. LUNG CANCER, 204(June 2025) [10.1016/j.lungcan.2025.108576]. Detail

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail

Gelsomino, F., Boni, L., Tiseo, M., Ricciardi, S., Rocco, D., Cortinovis, D., et al. (2025). An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04–2016. LUNG CANCER, 199(January 2025) [10.1016/j.lungcan.2024.108059]. Detail

Passarella, G., Canova, S., Abbate, M., Caspani, G., Sala, L., Russo, A., et al. (2025). The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer. DISCOVER ONCOLOGY, 16(1) [10.1007/s12672-025-01826-7]. Detail

Malighetti, F., Villa, M., Sala, E., Geeta, G., Arosio, G., Gemelli, M., et al. (2024). Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy. Intervento presentato a: American Association for Cancer Research Annual Meeting 2024 - April 5-10, 2024, San Diego, CA [10.1158/1538-7445.am2024-987]. Detail